Derval O'Carroll

Credit Suisse Securities (USA) LLC (Credit Suisse Securities USA) is the broker/dealer division of Credit Suisse Securities (USA) LLC, an investment banking company headquartered in New York City. The firm was founded in 1998 and is a wholly owned subsidiary of Credit Suisse (USA), Inc., ultimately owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Securities USA offers a suite of equities, solutions and credit products and services which includes global securities sales, trading and execution, prime brokerage and comprehensive investment research. Their clients include financial institutions, corporations, governments, institutional investors, such as pension funds and hedge funds, and private individuals around the world.

Deutsche Bank Securities, Inc. (DBSI) is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 1971 and is a wholly-owned investment banking and brokerage arm of DB U.S. Financial Markets Holding Corp., ultimately held by Deutsche Bank AG (NYSE: DB, FRA: DBK) in Germany. DBSI provides securities brokerage and investment advisory services to domestic and international private clients and institutions. They are also a primary dealer in US government securities as designated by the Federal Reserve.

Part of L3Harris Technologies, Inc., Coleman Research Corp. is a company that provides aviation and aeronautical engineering. The company is based in Orlando, FL. Coleman Research was acquired by L-3 Communications Holdings, Inc. from Thermo Electron Corp. on January 03, 2001 for $65 million.

Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ.

ING Financial Markets LLC (ING Financial) is a FINRA-registered broker/dealer headquartered in New York City. They have additional offices in Dallas, Houston and Los Angeles. The firm is a wholly-owned subsidiary of ING Financial Holdings Corp, itself a subsidiary of ING Groep NV (AMS: INGA) in The Netherlands. ING Financial offers a broad range of investment services to corporate and financial institutions, as well as other ING businesses. Their research team places a particular emphasis on emerging markets. Key product areas offered are: corporate and government debt, credit and equity derivatives, treasury products (including Repo and CP/CD issuance), interest rate derivatives, foreign exchange, structured products and securities financing.

Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA.

Primus Pharmaceuticals, Inc. provides prescription metabolic products to physicians and patients throughout North America. It offers prescription drug and medical food products. Its products include Alcortin A, Novacort, Fosteum, and Limbrel. The company was founded by Michael J. Martin and is headquartered in Scottsdale, AZ.

Part of CASI Pharmaceuticals, Inc., Cytokine Sciences, Inc. develops biopharmaceutical products that address the role of the blood and vessels. The company is based in Rockville, MD.

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA

InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany.

Founded in 2009 by Dr. Alex To, Cross Current Research LLC is an independent research firm located in Skillman, New Jersey. The firm offers comprehensive fundamental industry and company-specific research, as well as technical analysis of stocks and markets. They cover the healthcare, technology and financial services sectors. Cross Current Research offers services to institutional investors.

Part of Sanofi, Sanofi AB is a pharmaceutical company based in Stockholm, Sweden. The Swedish company's description states that it is an international pharmaceutical company.

Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA.

Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022.

Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.